secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001493152-24-012335
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies reports FY2023 revenue of $2.5M, up from $5K; CyPath Lung orders grow 350% in Q1 2024
--------------------------------------------------------------------------------

- FY2023 revenue $2.5M vs $5K in 2022; net loss $7.9M ($0.91/sh) vs $8.1M ($1.81/sh).
- Q4 2023 revenue $2.2M vs nil prior year; net loss $2.4M vs $1.7M.
- Cash and equivalents $2.8M at Dec 31, 2023.
- CMS final payment determination for CyPath Lung for 2024; CyPath Lung orders up 350% in Q1 2024 vs Q4 2023.
- Appointed Michael Dougherty as CFO; Dallas Coleman as National Director of Sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-012335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer